Clinical experience with the European ankylosing spondylitis infliximab cohort (EASIC): Long-term extension over 7 years with focus on clinical efficacy and safety

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 184-190

  Heldmann, Frank ^a   Baraliakos, Xenofon ^a   Kiltz, Uta ^a   Brandt, Jan ^b   Van Der Horst Bruinsma, Irene E ^c   Landewé, Robert ^d   Sieper, Joachim ^b   Burmester, Gert Rüdiger ^b   Van Den Bosch, Filip ^e   De Vlam, Kurt ^f   Gaston, Hill ^g,h   Gruenke, Mathias ⁱ   Witt, Mathias ⁱ   Appelboom, Thierry ^j   Emery, Paul ^k   Dougados, Maxime ^l   Leirisalo Repo, Marjatta ^m   Breban, Maxime ⁿ   Braun, Jürgen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j ERASME HOSPITAL   (Belgium)

^k UNIVERSITY OF LEEDS   (United Kingdom)

^l Institut Cochin   (France)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

Ankylosing spondylitis; Anti TNF; Infliximab

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BASAL CELL CARCINOMA; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HUMAN; INFECTION; INFUSION RELATED REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MELANOMA; OPPORTUNISTIC INFECTION; PATIENT GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SKIN CARCINOMA; SKIN INFECTION; TOXIC HEPATITIS; TUBERCULOSIS; UROGENITAL TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; COHORT ANALYSIS; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

ADULT; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963818158     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. BRAUN J, van der HEIJDE D: Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Invest Drugs 2003; 12: 1097-109
2. BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondyloarthropathies in HLA B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67
3. SIEPER J, BRAUN J, RUDWALEIT M, BOONEN A, ZINK A: Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 (Suppl. 3): iii8-18
4. BRAUN J, van den BERG R, BARALIAKOS X et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904
5. van der HEIJDE D, SIEPER J, MAKSYMOVYCH WP et al.: Assessment of SpondyloArthritis International Society: 2010 Update of the International ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-8
6. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93
7. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52
8. BRANDT J, HAIBEL H, SIEPER J, REDDIG J, BRAUN J: Infliximab treatment of severe ankylosing spondylitis: one-year follow-up (letter). Arthritis Rheum 2001; 45: 2936-7
9. BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month openlabel study. Rheumatology 2002; 41: 1280-5
10. BRAUN J, BRANDT J, LISTING J et al.: Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an openlabel, observational extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33
11. VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.; and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Efficacy and safety of infliximab in patients with Ankylosing Spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91
12. BRAUN J, DEODHAR A, DIJKMANS B et al.; Ankylosing Spondylits Study for the evaluation of Recombinant Infliximab Therapy Study Group: Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59: 1270-8
13. BRAUN J, LANDEWé R, HERMANN KG et al.; ASSERT Study Group: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, doubleblind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54: 1646-52
14. BARALIAKOS X, LISTING J, BRANDT J et al.: Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the TNF-alpha antibody infliximab. Rheumatology 2007; 46: 1450-3
15. BARALIAKOS X, LISTING J, RUDWALEIT M, BRANDT J, SIEPER J, BRAUN J: Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005; 64: 1462-6
16. BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S164-7
17. Van der HEIJDE D, LANDEWé R, EINSTEIN S et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324-31
18. Van der HEIJDE D, LANDEWé R, BARALIAKOS X et al.: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Arthritis Rheum 2008; 58: 3063-70
19. Van der HEIJDE D, LANDEWé R, MAKSYMOVYCH W et al.: Adalimumab (Humira) Therapy for Ankylosing Spondylitis over 2 years does not demonstrate inhibition of radiographic progression compared with a historical control group. Abstract 670; ACR 2008
20. BRAUN J, BARALIAKOS X, LISTING J et al.: Persistent clinical efficacy and safety of antitumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67: 340-5
21. BARALIAKOS X, LISTING J, FRITZ C et al.: Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis-early clinical repsonse predicts long-term outcome. Rheumatology 2011; 50: 1690-9
22. HELDMANN F, BRANDT J, van der HORSTBRUINSMA IE et al.: The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80
23. SAOUGOU I, MARKATSELI TE, VOULGARI PV, DROSOS AA: Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010; 77: 325-9
24. MARTIN-MOLA E, SIEPER J, LEIRISALOREPO M et al.: Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28: 238-45
25. BOONEN A, MAU W: The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S112-7
26. FRANKE LC, AMENT AJ, van de LAAR MA, BOONEN A, SEVERENS JL: Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55), S118-23
27. Van der HEIJDE D, DOUGADOS M, DAVIS J et al.: ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005; 52: 386-94
28. ZOCHLING J, BRAUN J: Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S88-92
29. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91
30. CALIN A, GARRETT S, WHITELOCK H et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5
31. JENKINSON TR, MALLORIE PA, WHITELOCK HC, KENNEDY LG, GARRETT SL, CALIN A: Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8
32. van der HEIJDE D, LANDEWé R, FELDTKELLER E: Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008; 67: 489-93
33. BARALIAKOS X, HELDMANN F, VAN DER HEIJDE D et al.: Radigraphic findings after 5 years of infliximab treatment in patients with ankylosing spondylitis. ACR 2010
34. BRAUN J, SIEPER J: What is the most important outcome parameter in ankylosing spondylitis? Rheumatology 2008; 47: 1738-40
35. VESOVIC-POTIC V, MUSTUR D, STANISAVLJEVIC D, ILLE T, ILLE M: Relationship betweeen spinal mobility measures and quality of life in patients with ankylosing spondylitis. Rheumatol Int 2009; 29: 879-84
36. MACHADO P, LANDEWé R, BRAUN J, HERMANN KG, BAKER D, van der HEIJDE D: Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1465-70
37. WANDERS A, LANDEWé R, DOUGADOS M, MIELANTS H, van der LINDEN S, van der HEIJDE D: Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005; 64: 988-94
38. CHEN HA, CHEN CH, LIAO HT et al.: Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis. Semin Arthritis Rheum 2011; 40: 552-8
39. VANDER CRUYSSEN B, MUNOZ-GOMARIZ E, FONT P et al.; ASPECT-REGISPONSER-RE-SPONDIA working group: Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology 2010; 49: 73-81
40. BARALIAKOS X, BRAUN J: Hip involvement in ankylosing spondylitis: what is the verdict? Rheumatology 2010; 49: 3-4
41. PODDUBNYY D, RUDWALEIT M, HAIBEL H et al.: Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71: 1616-22
42. WANDERS A, van der HEIJDE D, LANDEWé R et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-65
43. LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12
44. ZINK A, ASKLING J, DIXON WG, KLARESKOG L, SILMAN AJ, SYMMONS DP: European Biologics Registers-Methodology, selected results, and perspectives. Ann Rheum Dis 2009; 68: 1240-6.
45. STRANGFELD A, HIERSE F, RAU R et al.: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12: R5
46. BURMESTER GR, PANACCIONE R, GORDON KB, MCILRAITH MJ, LACERDA AP: Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn's disease. Ann Rheum Dis 2012 Epub ahead of print
47. ASKLING J, BAECKLUND E, GRANATH F et al.: Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-53
48. ASKLING J, KLARESKOG L, BLOMQVIST P, FORED M, FELTELIUS N: Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65: 1184-7
49. BARALIAKOS X, LISTING J, RUDWALEIT M et al.: Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007; 34: 510-5
50. KO JM, GOTTLIEB AB, KERBLESKI JF: Induction and exacerbation of psoriasis with TNFblockade therapy: J Dermatol Treat 2009; 20: 100-8
51. KIRCIK LH, Del ROSSO JQ: Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009; 8: 546-59
52. der HEIJDE D, HAIBEL H, RUDWALEIT M, SIEPER J: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor a agents. Arthritis Rheum 2007; 57: 639-47
53. LIM LL, FRAUNFELDER FW, ROSENBAUM JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56: 3248-52
54. BRAUN J, BARALIAKOS X, LISTING J, SIEPER J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51
55. van der HEIJDE DM, REVICKI DA, GOOCH KL et al.; ATLAS Study Group: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009; 11: R124